Therapeutic monitoring of the potent, highly lipophilic glucocorticoid, flu
ticasone propionate (FP), was initially performed by a radioimmunoassay met
hod. However an improved method with a lower limit of quantitation (LLOQ) o
f at least 25 pg per ml (pg ml(-1)) was needed to measure the low levels of
FP present in human plasma following inhalation administration of doses in
the range 50-250 mu g twice daily. A sensitive and specific liquid chromat
ographic, tandem mass spectrometric method (LC-MS/MS) with automated solid
phase extraction (SPE) was developed and validated. Fluticasone propionate
was extracted from plasma using Bond Elut C18 cartridges and analysed using
reverse-phase chromatography with atmospheric pressure chemical ionisation
followed by selective reaction monitoring. The method used a C-13-labelled
internal standard and was validated over a concentration range of 25-500 p
g ml(-1). The method was shown to be specific, sensitive and reliable in th
e analysis of clinical samples. The main advantages of this method over the
radioimmunoassay method previously used were improved sensitivity, specifi
city, ease of sample preparation and shortened analysis time. (C) 1999 Else
vier Science B.V. All rights reserved.